TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1646442

Group type: EXPERIMENTAL
Intervention: Intervention not specified; only one study suggested an effect on repetition frequency of suicide attempts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; only one study suggested an effect on repetition frequency of suicide attempts.
Number of subjects: 0
Study: 7346693

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus Aspirin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30768132

Group type: EXPERIMENTAL
Intervention: Cooled perch (CP)
Number of subjects: 36
Study: 28807037

Group type: EXPERIMENTAL
Intervention: Selepressin 2.5 ng/kg/minute
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 25037960

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg IV)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 25804372

Group type: COMPARATOR
Intervention: Intact group (no ligament injury)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Injured group (with SL and/or LT injury)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (comparison)
Number of subjects: 40
Study: 23399688

Group type: EXPERIMENTAL
Intervention: Lower numeracy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adjusted analyses
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Numeracy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low numeracy
Number of subjects: 150
Study: 21280190

Group type: EXPERIMENTAL
Intervention: Tacrolimus qd (once-daily formulation)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tacrolimus bid (twice-daily formulation)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 129
Study: 20058595

Group type: EXPERIMENTAL
Intervention: Serum proteomics profiling using SELDI‐TOF MS
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Protein peaks M4168.94 and M1122.57
Number of subjects: 56
Study: 17013435

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 14641441

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Optibond Plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Admira Bond
Number of subjects: 60
Study: 11049783

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 374

Group type: COMPARATOR
Intervention: 0.5% tincture of chlorhexidine
Number of subjects: 374
Study: 9805329

Group type: EXPERIMENTAL
Intervention: Cognitive skill learning intervention with immediate feedback
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive skill learning intervention with additional trials and immediate feedback
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (normal participants)
Number of subjects: 26
Study: 8031477

Group type: EXPERIMENTAL
Intervention: Active prebrushing dental rinse (Advanced Formula Plax)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 2510968

Group type: EXPERIMENTAL
Intervention: Stainless Steel Ring (SS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Copper T220 (TCu)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (LNG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (before exposure)
Number of subjects: 96
Study: 16749

Group type: EXPERIMENTAL
Intervention: Each of the 5 antacids
Number of subjects: 25
Study: 29979488

Group type: EXPERIMENTAL
Intervention: Blue-light flexible cystoscopy (BLFC) with hexaminolevulinate
Number of subjects: 304
Study: 28667510

Group type: EXPERIMENTAL
Intervention: Ganaxolone (200, 400, and 600 mg twice daily for 6 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 25649275

Group type: EXPERIMENTAL
Intervention: Placebo treatment session with inert aqueous cream
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control session with inert aqueous cream
Number of subjects: 48
Study: 23841808

Group type: EXPERIMENTAL
Intervention: 0.83 M concentration of sucrose in water
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rated sucrose liking
Number of subjects: 16
Study: 21371717

Group type: EXPERIMENTAL
Intervention: Sequential therapy (amoxicillin and omeprazole for 5 days followed by clarithromycin, tinidazole, and omeprazole for 5 days)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin and clarithromycin plus omeprazole for 7 days followed by placebo for 3 days)
Number of subjects: 107
Study: 19593017

Group type: EXPERIMENTAL
Intervention: Internet‐based education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face to face education with a nurse
Number of subjects: 0
Study: 16813788

Group type: EXPERIMENTAL
Intervention: Computerized hydraulic knee (Otto Bock C‐leg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Noncomputerized hydraulic knee (Ossur Mauch SNS)
Number of subjects: 8
Study: 12865832

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 115
Study: 10936666

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Diabetic patients with longer duration of diabetes
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Diabetic patients on insulin treatment
Number of subjects: 204
Study: 9595578

Group type: COMPARATOR
Intervention: Ketorolac 1.2 mg/kg every six hrs (Protocol A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ketorolac 1.2 mg/kg (bolus) + 0.21 mg/kg/hr (Protocol B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fentanyl 1 gamma/kg/hr (Protocol C)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 gamma/kg/hr + Ketorolac 0.21 mg/kg/hr (Protocol D)
Number of subjects: 52
Study: 7528310

Group type: EXPERIMENTAL
Intervention: Withholding blood containing NANB surrogate positive units
Number of subjects: 4588

Group type: COMPARATOR
Intervention: No withholding of blood containing NANB surrogate positive units
Number of subjects: 4588

Group type: EXPERIMENTAL
Intervention: Syngeneic blood (non-randomised cohort)
Number of subjects: 4588
Study: 2687198

Group type: EXPERIMENTAL
Intervention: Optiray 320 mg I/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omnipaque 300 mg I/mL
Number of subjects: 60
Study: 30891748

Group type: EXPERIMENTAL
Intervention: Individualized and progressive multicomponent exercise at moderate intensity for 6 months
Number of subjects: 112
Study: 28501679

Group type: EXPERIMENTAL
Intervention: specialist depression team arm
Number of subjects: 187

Group type: COMPARATOR
Intervention: general mental health arm
Number of subjects: 187
Study: 25338833

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided antegrade CFA puncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy-assisted antegrade CFA puncture
Number of subjects: 100
Study: 23107599

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 14

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14
Study: 21616596

Group type: EXPERIMENTAL
Intervention: Acupuncture (verum acupuncture plus placebo)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham acupuncture plus flunarizine (Control)
Number of subjects: 140
Study: 18452199

Group type: EXPERIMENTAL
Intervention: Infliximab initiation
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (no infliximab)
Number of subjects: 494
Study: 17130196

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study: 12963704

Group type: COMPARATOR
Intervention: FU + LV (bolus FU 425 mg/m2 + LV 20 mg/m2 on days 1 to 5, repeated on day 28)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: FU24h (FU 2600 mg/m2 as a 24-hour infusion)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: FU24h + LV (FU 2600 mg/m2 as a 24-hour infusion + LV 500 mg/m2)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: FU24h + LV
Number of subjects: 497

Group type: COMPARATOR
Intervention: FU + LV
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: FU24h
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 497
Study: 10792163

Group type: EXPERIMENTAL
Intervention: Beta-sitosterol treatment continued for 18 months (38 patients)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: No further therapy after beta-sitosterol (41 patients)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Beta-sitosterol treatment started after placebo (27 patients)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No further therapy after placebo (18 patients)
Number of subjects: 117
Study: 9076206

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 8472740

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 30
Study: 3888239

Group type: EXPERIMENTAL
Intervention: Labetalol pretreatment (0.5 mg kg‐1 bolus followed by 0.1 mg kg‐1 h‐1 infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31375651

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 228
Study: 29941810

Group type: EXPERIMENTAL
Intervention: Astaxanthin (4 mg capsule)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 26467417

Group type: EXPERIMENTAL
Intervention: Land exercise
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: No-exercise
Number of subjects: 53
Study: 24549687

Group type: EXPERIMENTAL
Intervention: Forced Choice Testing (FCT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Modified Cognitive Interviewing (MCI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FCT paired with MCI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Autobiographical Implicit Association Testing (aIAT)
Number of subjects: 64
Study: 22968615

Group type: EXPERIMENTAL
Intervention: Combined therapy with antibiotics and superlimf
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with antibiotics
Number of subjects: 0
Study: 20368400

Group type: EXPERIMENTAL
Intervention: Genius dialysis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Standard hemodialysis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 15
Study: 18547224

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 40
Study: 16060202

Group type: EXPERIMENTAL
Intervention: Piper methysticum 30C
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Plumbum metallicum 30C
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12161978

Group type: EXPERIMENTAL
Intervention: EPO treated group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 10528604

Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (VP) at 0.04 U/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10707717

Group type: EXPERIMENTAL
Intervention: Roxatidine (75 mg bid)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 53
Study: 2183710

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (750 mg twice a day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous broad-spectrum cephalosporin or nafcillin-aminoglycoside combination
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 59
Study: 6119933

Group type: COMPARATOR
Intervention: Intramuscular narcotic analgesic ketobemidone
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% bupivacaine‐epinephrine intercostal nerve block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural morphine (4 mg)
Number of subjects: 90
Study: 31689905

Group type: EXPERIMENTAL
Intervention: Educator-led daily Energisers (3 brief 5-minute sessions each day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal practice in control ECEC centres
Number of subjects: 14
Study: 29040538

Group type: EXPERIMENTAL
Intervention: 15 min of supine immobilization after IUI
Number of subjects: 498

Group type: COMPARATOR
Intervention: Immediate mobilization after IUI
Number of subjects: 498
Study: 25889322

Group type: EXPERIMENTAL
Intervention: Durolane (3.0 ml injection at week 0)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Artz (five 2.5 ml injections at weeks 0, 1, 2, 3, and 4)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Artz
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Durolane
Number of subjects: 349
Study: 24917003

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) 22.5 mg subcutaneously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) 30 mg subcutaneously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) administered intramuscularly
Number of subjects: 12
Study: 23040735

Group type: EXPERIMENTAL
Intervention: 3-digit CPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-digit CPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-digit CPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shapes CPT
Number of subjects: 0
Study: 19863831

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Current physiotherapy practice without in‐exsufflation
Number of subjects: 8
Study: 17070743

Group type: EXPERIMENTAL
Intervention: Bed rest with supine treadmill exercise within lower body negative pressure (LBNP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary bed rest (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bed rest with supine treadmill exercise within LBNP
Number of subjects: 14
Study: 15279525

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance established early in treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion regulation capacity during Phase 2 exposure therapy
Number of subjects: 0
Study: 11521689

Group type: EXPERIMENTAL
Intervention: Three-dimensional optic disc algorithm applied to Topcon Image-net
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 100
Study: 9691877

Group type: EXPERIMENTAL
Intervention: LMA-Unique
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 100
Study: 7871661

Group type: EXPERIMENTAL
Intervention: Sympathetic block (subpleural and stellate ganglion blocks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enteral feeding initiated early after pain relief
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sympathetic block and early enteral feeding
Number of subjects: 50
Study: 3281431

Group type: EXPERIMENTAL
Intervention: Low dose aspirin after early thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31466119

Group type: EXPERIMENTAL
Intervention: Delgocitinib ointment 30 mg g-1
Number of subjects: 91

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Delgocitinib ointment 30 mg g-1 and Vehicle ointment
Number of subjects: 91
Study: 30419113

Group type: EXPERIMENTAL
Intervention: Lifetime ASCVD risk (50% lifetime ASCVD event risk)
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: 10-year ASCVD event risk (15% 10-year ASCVD event risk)
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: 10-year CVD death risk (4% 10-year cardiovascular disease death risk)
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Pictogram risk display
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Bar graph risk display
Number of subjects: 2708

Group type: COMPARATOR
Intervention: No graphic risk display
Number of subjects: 2708
Study: 28113021

Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Tablets (100 µg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Subcutaneous Morphine (5 mg)
Number of subjects: 114
Study: 26271059

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 7364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7364
Study: 24156640

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 21138561

Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, home-based, self-management physical activity program
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: High intensity, structured, supervised exercise program
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 18240230

Group type: EXPERIMENTAL
Intervention: TNFalpha antagonists
Number of subjects: 3

Group type: COMPARATOR
Intervention: No TNFalpha antagonists
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3
Study: 17040151

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 184

Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Palliative care (staff)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Supportive care (staff)
Number of subjects: 184
Study: 12723463

Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan with 400 mg ketoconazole once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: 12.5 mg almotriptan alone
Number of subjects: 16
Study: 11102255

Group type: EXPERIMENTAL
Intervention: Lefradafiban 30 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Lefradafiban 20 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Lefradafiban 45 mg
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Lefradafiban (all doses)
Number of subjects: 531
Study: 9297998

Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (four 1.0 mg/kg doses of intramuscular methotrexate alternated with 0.1 mg/kg oral folinic acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 100
Study: 7688379

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (12 IU/day x 12 days) with HMG/buserelin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment with HMG
Number of subjects: 40
Study: 3472476

Group type: EXPERIMENTAL
Intervention: Lidocaine plus diflunisal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29330620

Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27733151

Group type: EXPERIMENTAL
Intervention: Soluble fiber (10.5 g daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 40
Study: 23635882

Group type: EXPERIMENTAL
Intervention: Participants with higher levels of social anxiety
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Negative performance expectations and self-focused attention
Number of subjects: 161
Study: 23698064

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COC) and progestin‐only pills (POP)
Number of subjects: 4913

Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception
Number of subjects: 4913

Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception (unweighted site‐adjusted model)
Number of subjects: 4913

Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception (baseline factor adjusted model)
Number of subjects: 4913
Study: 20144259

Group type: EXPERIMENTAL
Intervention: School-based multi-component education intervention
Number of subjects: 579

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 579
Study: 19061734

Group type: EXPERIMENTAL
Intervention: Cognitive-didactic treatment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Functional-experiential treatment
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cognitive-didactic treatment (younger participants)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Functional-experiential treatment (participants older than 30 years)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Functional-experiential treatment (participants with more years of education)
Number of subjects: 360
Study: 16181531

Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban Capsule (QYXB) and conventional medicine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional medicine alone
Number of subjects: 80
Study: 12562408

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (50 mg x kg(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 24
Study: 10562780

Group type: EXPERIMENTAL
Intervention: Therapeutic tape (TT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison tape (CT)
Number of subjects: 70
Study: 8546093

Group type: EXPERIMENTAL
Intervention: Lovastatin intervention for coronary restenosis, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1870249

Group type: EXPERIMENTAL
Intervention: Intensive HIV/AIDS intervention program (up to 30 sessions)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 145
Study: 6855804

Group type: EXPERIMENTAL
Intervention: Dichlorophenamide
Number of subjects: 3